Skip to main content
Terug
WUXIF logo

WuXi AppTec Co., Ltd.

Datakwaliteit: 100%
Oversold
WUXIF
OTC Healthcare Medical - Diagnostics & Research
€ 13,88
€ 0,00 (0,00%)
Marktkapitalisatie: 41,41B
Ook genoteerd als WUXAY OTC
Dagbereik
€ 13,88 € 15,00
52-Weeksbereik
€ 7,34 € 16,80
Volume
600
50D / 200D Gem.
€ 14,12 / € 12,83
Vorige Slotkoers
€ 13,88

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 4,4 0,3
P/B 0,7 2,9
ROE % 16,6 3,7
Net Margin % 24,1 3,8
Rev Growth 5Y % 24,1 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 € 7,38
€ 6,90 – € 8,04
 68 B 1
FY2027 € 6,43
€ 6,01 – € 7,01
 59 B 1
FY2026 € 5,60
€ 5,24 – € 6,10
 52 B 1

Belangrijkste Punten

Revenue grew 24,12% annually over 5 years — strong growth
ROE of 16,62% — decent returns on equity
Net margin of 24,08% shows strong profitability
Debt/Equity of 0,08 — conservative balance sheet
Generating 8,40B in free cash flow
P/E of 4,38 — trading at a low valuation

Groei

Revenue Growth (5Y)
24,12%
Revenue (1Y)-2,73%
Earnings (1Y)-1,63%
FCF Growth (3Y)259,46%

Kwaliteit

Return on Equity
16,62%
ROIC13,70%
Net Margin24,08%
Op. Margin29,51%

Veiligheid

Debt / Equity
0,08
Current Ratio2,38
Interest Coverage53,60

Waardering

P/E Ratio
4,38
P/B Ratio0,71
EV/EBITDA2,40
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2,73% Revenue Growth (3Y) -0,14%
Earnings Growth (1Y) -1,63% Earnings Growth (3Y) 3,55%
Revenue Growth (5Y) 24,12% Earnings Growth (5Y) 33,67%
Profitability
Revenue (TTM) 39,24B Net Income (TTM) 9,45B
ROE 16,62% ROA 11,76%
Gross Margin 41,48% Operating Margin 29,51%
Net Margin 24,08% Free Cash Flow (TTM) 8,40B
ROIC 13,70% FCF Growth (3Y) 259,46%
Safety
Debt / Equity 0,08 Current Ratio 2,38
Interest Coverage 53,60 Dividend Yield 0,02%
Valuation
P/E Ratio 4,38 P/B Ratio 0,71
P/S Ratio 1,06 PEG Ratio 12,27
EV/EBITDA 2,40 Dividend Yield 0,02%
Market Cap 41,41B Enterprise Value 27,84B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 39,24B 40,34B 39,35B 22,90B 16,54B
Net Income 9,45B 9,61B 8,81B 5,10B 2,96B
EPS (Diluted) 3,26 3,24 2,82 1,73 1,05
Gross Profit 16,28B 16,57B 14,68B 8,31B 6,28B
Operating Income 11,58B 11,87B 10,65B 6,04B 3,39B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 80,33B 73,67B 64,69B 55,13B 46,29B
Total Liabilities 21,24B 18,15B 17,76B 16,37B 13,57B
Shareholders' Equity 58,63B 55,12B 46,59B 38,49B 32,49B
Total Debt 4,75B 5,45B 5,87B 4,28B 4,29B
Cash & Equivalents 18,32B 13,76B 7,99B 8,24B 10,24B
Current Assets 38,69B 30,42B 24,00B 21,99B 23,06B
Current Liabilities 16,23B 14,76B 14,50B 12,98B 7,92B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#106 of 827
63
Custom Contrarian Investing (David Dreman)
#247 of 670
39
Value Defensive Investing (Benjamin Graham)
#76 of 709
59

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026